HMG-CoA reductase inhibitors: Issues in assessing their benefits in coronary heart disease

Antonio Gotto

doi:10.2165/00002018-199614010-00002

HMG-CoA reductase inhibitors: Issues in assessing their benefits in coronary heart disease

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	8-10
Number of pages	3
Journal	Drug Safety
Volume	14
Issue number	1
DOIs	https://doi.org/10.2165/00002018-199614010-00002
State	Published - Jan 1 1996

ASJC Scopus subject areas

Toxicology
Pharmacology
Pharmacology (medical)

Access to Document

10.2165/00002018-199614010-00002

Cite this

@article{28173a27dec2454e9fc2216f52b6cfa4,

title = "HMG-CoA reductase inhibitors: Issues in assessing their benefits in coronary heart disease",

author = "Antonio Gotto",

year = "1996",

month = jan,

day = "1",

doi = "10.2165/00002018-199614010-00002",

language = "English (US)",

volume = "14",

pages = "8--10",

journal = "Drug Safety",

issn = "0114-5916",

publisher = "Adis",

number = "1",

}

TY - JOUR

T1 - HMG-CoA reductase inhibitors

T2 - Issues in assessing their benefits in coronary heart disease

AU - Gotto, Antonio

PY - 1996/1/1

Y1 - 1996/1/1

UR - https://www.scopus.com/pages/publications/0030027290

UR - https://www.scopus.com/inward/citedby.url?scp=0030027290&partnerID=8YFLogxK

U2 - 10.2165/00002018-199614010-00002

DO - 10.2165/00002018-199614010-00002

M3 - Editorial

C2 - 8713484

AN - SCOPUS:0030027290

SN - 0114-5916

VL - 14

SP - 8

EP - 10

JO - Drug Safety

JF - Drug Safety

IS - 1

ER -

HMG-CoA reductase inhibitors: Issues in assessing their benefits in coronary heart disease

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this